New data at EHA backs Sanofi, Innate’s NK cell engager

One of the lead candidates in Sanofi natural killer (NK) cell engager alliance with Innate Pharma has shown encouraging and durable efficacy in various haematological cancers, according to a phase 1/2 study presented at the EHA congress.SAR443579 (also known as IPH6101) is a trifunctional NKp46/CD16-based anti-CD123 NK cell engager – described as a first-in-class therapy – that has now advanced into a phase 2 programme. It was the first candidate taken forward by Sanofi after it signed its first partnership with Innate in 2016.